Key Takeaways
UnitedHealth Group (NYSE: UNH) and Bristol-Myers Squibb (NYSE: BMY) stand out in the healthcare sector, not just for their market dominance, but for their consistent dividend payouts, making them attractive to institutional investors and hedge funds seeking stable income. As of May 24, 2026, both companies feature prominently in "best dividend stocks" lists, with UNH offering a 2.3% dividend yield and BMY a more substantial 4.2% yield. This institutional interest is driven by a blend of defensive characteristics, strong cash flow generation, and the potential for long-term value, even as each company navigates its unique set of challenges.
Hedge funds, often associated with high-growth, volatile plays, frequently allocate capital to established dividend payers like UNH and BMY for portfolio diversification and income stability. For instance, UNH was recently cited among the "12 Best Dividend Stocks to Invest in According to Hedge Funds" by Sultan Khalid on Yahoo Finance on May 24, 2026. This reflects a broader strategy among sophisticated investors to balance risk with consistent returns, particularly in sectors like healthcare that tend to be less cyclical. However, a deeper dive reveals that while both are dividend darlings, their underlying narratives and future prospects diverge significantly, demanding a careful evaluation of their individual merits and risks.
The appeal of these healthcare giants to institutional money is not merely about yield; it's about the perceived resilience of their business models. UNH, with its integrated healthcare services, and BMY, with its biopharmaceutical pipeline, operate in essential, non-discretionary segments of the economy. This inherent stability, coupled with a commitment to shareholder returns through dividends, positions them as anchors in many institutional portfolios. However, the current market environment, characterized by evolving regulatory landscapes and patent cliffs, means that even these stalwarts are not without their complexities, requiring investors to look beyond the headline dividend yield.
UnitedHealth Group (UNH), a healthcare behemoth with a market capitalization of $352.79 billion, continues to demonstrate robust top-line expansion, yet its profitability and cash flow metrics reveal underlying pressures. For the full year 2025, UNH reported consolidated revenues of $447.6 billion, marking a 12% year-over-year growth. This impressive revenue trajectory is largely fueled by its dual engines: UnitedHealthcare, its insurance arm, and Optum, its health services segment. The company's Q1 2026 results comfortably exceeded estimates, leading to an upward revision of its full-year 2026 adjusted earnings outlook to more than $18.25 per share, up from the prior forecast of over $17.75.
Despite this revenue strength, UNH's TTM net income growth saw a significant decline of -16.3% year-over-year for FY2025, with EPS falling -14.7%. Operating cash flow also decreased by -18.6%, and free cash flow by -22.4%. These contractions are not indicative of a failing business, but rather reflect the "perfect storm" of risks UNH faces in 2026, particularly from the regulatory environment. The Department of Justice (DOJ) is conducting a wide-ranging antitrust probe into the relationship between UnitedHealthcare and Optum’s physician groups, investigating potential monopolistic practices. This scrutiny, alongside the shadow of the 2024 Change Healthcare cyberattack, creates significant reputational and operational challenges.
Furthermore, the Centers for Medicare & Medicaid Services (CMS) announced flat reimbursement rates for 2027, a critical development given that medical costs are rising by 6-8% annually. This creates a substantial "margin squeeze" for UNH's highly profitable Medicare Advantage (MA) segment in 2026 and 2027. The recently passed Consolidated Appropriations Act of 2026 also includes "delinking" provisions for Pharmacy Benefit Managers (PBMs) like OptumRx, which will necessitate a restructuring of how OptumRx generates profit, moving away from drug list price percentages. While UNH is investing $1.5 billion in an "AI-first security architecture" and deploying AI agents to handle 40% of routine claims processing, these innovations must overcome significant external pressures to translate into sustainable profit growth.
UnitedHealth Group's formidable market position and innovative strides are currently overshadowed by several significant headwinds that could impact its near-term financial performance and investor sentiment. The most pressing concern is the escalating regulatory scrutiny, particularly the Department of Justice's (DOJ) antitrust probe. This investigation focuses on the vertical integration between UnitedHealthcare and Optum, specifically whether Optum's acquisition of physician groups creates an unfair monopoly that disadvantages independent doctors and stifles competition. Such probes can lead to substantial legal costs, operational restrictions, and a chilling effect on future growth strategies.
Another critical challenge stems from Medicare Advantage (MA) reimbursement rates. The federal government's decision to implement flat reimbursement rates for 2027, coupled with an estimated 6-8% annual increase in medical costs, presents a direct threat to UNH's margins. This "margin squeeze" is exacerbated by a persistent spike in "outpatient utilization" since 2023, driven by the aging U.S. population ("Silver Tsunami") and the rising cost of new treatments like GLP-1 weight-loss drugs. UNH acknowledged a $100 million unfavorable development in medical reserves during Q4 2025, signaling potential difficulties in managing future healthcare expenditures.
The PBM reform landscape also poses a substantial risk to OptumRx, a key component of UNH's Optum segment. Bipartisan support for "de-linking" PBM fees from drug prices, as outlined in the Consolidated Appropriations Act of 2026, could fundamentally alter OptumRx's profitability model. Traditionally, PBMs have generated revenue based on a percentage of a drug's list price, a practice now under intense legislative pressure. This necessitates a complete overhaul of OptumRx's revenue generation strategy, introducing uncertainty into a previously reliable profit center. These regulatory and cost pressures have led some major investment banks to downgrade UNH from "Strong Buy" to "Hold" following its January 2026 crash, reflecting cautious optimism on Wall Street.
Bristol-Myers Squibb (BMY), with a market capitalization of $121.42 billion, presents a compelling case for income investors, boasting a TTM dividend yield of 4.2% and a 17-year streak of annual dividend increases. However, the biopharmaceutical giant is at a critical juncture, navigating the impending patent expiration for its blockbuster blood thinner, Eliquis, which is expected to significantly impact revenue. Indeed, BMY's total revenue declined to $21.8 billion in 2025, down from $25.7 billion in 2024, largely due to these patent concerns. The company anticipates total revenue for 2026 to fall between $46 billion and $47.5 billion, compared to the $48.2 billion reported in 2025, reflecting the ongoing challenges.
Despite these headwinds, BMY's Q1 2026 results, released on April 30, 2026, showed resilience, with the company reaffirming its 2026 financial guidance. Management expects total revenues and diluted EPS to trend toward the upper end of its projected ranges, with diluted EPS guided between $6.05 and $6.35. This confidence is underpinned by the strong performance of its "growth portfolio," which saw sales rise from $22.6 billion in 2024 to $26.4 billion in 2025, partially offsetting the decline from legacy products. Key to this growth are new product launches and strategic collaborations, such as the recent agreement with Anthropic to deploy Claude Enterprise as a shared intelligence platform across its global operations, announced on May 20, 2026.
BMY's robust R&D pipeline is focused on high-impact, transformational medicines, particularly in oncology and neuroscience. Recent developments include European Commission approval of Sotyktu (deucravacitinib) for active psoriatic arthritis in adults on May 8, 2026, and new data presentations at ASCO® 2026 demonstrating the strength of its oncology portfolio. The company's TTM net income growth of 178.8% and EPS growth of 178.2% for FY2025, while impressive, are largely a recovery from previous lows, and future growth will depend heavily on successful pipeline execution and new product uptake. With a low beta of 0.2, BMY offers stability, but its long-term trajectory hinges on its ability to effectively replace revenue from expiring patents with new, innovative therapies.
Institutional investor sentiment towards Bristol-Myers Squibb (BMY) in Q1 2026 appears mixed, reflecting the company's dual narrative of patent challenges and pipeline potential. According to HedgeFollow data for Q1 2026, while a significant number of institutional investors added shares, a nearly equal number decreased their positions. Specifically, 1,163 institutional investors added BMY shares to their portfolios, while 1,123 decreased their holdings. This suggests a nuanced approach, with some funds betting on the company's long-term pipeline and valuation, while others are de-risking amidst patent concerns.
Among the notable moves in Q4 2025, UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC, removed a substantial 65,718,198 shares, valued at an estimated $3.54 billion. Conversely, AQR CAPITAL MANAGEMENT LLC added 16,332,924 shares, representing a +172.6% increase in their portfolio, valued at an estimated $880.99 million. These large, opposing trades highlight the divergent views among sophisticated investors regarding BMY's future. More recently, as of May 13, 2026, First Trust Advisors LP increased its BMY position by +4.6%, holding 5,534,556 shares worth $335.67 million, while CI Investments Inc. decreased its position by -5.9%.
Analyst ratings also reflect this cautious optimism. Based on an analysis of 29 Wall Street analysts, BMY holds a "Hold" consensus rating, with 10 "Buy" ratings, 18 "Hold" ratings, and 1 "Sell" rating. The median price target is $65.00, implying a 9.3% upside from the current price of $59.46. Citi analyst Geoff Meacham raised his price objective on BMY to $60 from $53 on January 27, 2026, maintaining a "Neutral" rating, citing a more favorable sector setup for 2026. This suggests that while BMY's valuation multiples, such as a P/E of 16.70 and P/FCF of 10.20, are attractive compared to the broader market, the market remains watchful of its ability to execute on its pipeline and mitigate patent expiry impacts.
When comparing UnitedHealth Group (UNH) and Bristol-Myers Squibb (BMY) for long-term dividend appeal, investors must weigh their distinct risk-reward profiles. UNH, despite its lower dividend yield of 2.3% compared to BMY's 4.2%, has demonstrated superior revenue growth, with a 11.8% YoY increase for FY2025, versus BMY's slight decline of -0.2%. However, UNH's dividend growth for FY2025 was 7.3%, outpacing BMY's 3.0%. Both companies maintain healthy dividend payout ratios, with UNH at 66.5% and BMY at 69.7%, suggesting sustainability.
From a valuation perspective, BMY appears more attractive on traditional metrics, trading at a P/E of 16.70 and P/S of 2.50, significantly lower than UNH's P/E of 29.35 and P/S of 0.78. BMY also boasts a higher FCF yield of 9.8% compared to UNH's 5.6%, indicating stronger cash generation relative to its market cap. This suggests that BMY offers a more compelling value proposition for income-focused investors willing to tolerate the patent cliff risks. However, UNH's dominant market position, diversified business model through Optum, and aggressive investment in AI for efficiency and cost management provide a robust foundation for future earnings, even if current regulatory pressures are impacting profitability.
The long-term outlook for UNH hinges on its ability to navigate the complex regulatory environment, particularly the DOJ antitrust probe and the Medicare Advantage reimbursement squeeze. Its strategic pivot towards "Value-Based Care" and AI integration could unlock significant efficiencies and new revenue streams, but these initiatives will take time to fully materialize. For BMY, success depends on its R&D pipeline delivering new blockbusters to offset the revenue decline from Eliquis. Its strong gross margins of 68.7% and operating margins of 25.7% (compared to UNH's 18.8% and 4.2% respectively) highlight the inherent profitability of its biopharmaceutical model, provided it can maintain product innovation. Ultimately, UNH offers growth with regulatory risk, while BMY offers value with pipeline execution risk.
For investors prioritizing immediate income and a lower valuation, Bristol-Myers Squibb presents a compelling option, provided they are comfortable with the company's ability to innovate past its patent challenges. Those seeking a more diversified healthcare play with a strong track record of growth and a strategic focus on future healthcare trends, despite current regulatory headwinds, might lean towards UnitedHealth Group. Both companies remain significant players in the healthcare sector, and their inclusion in hedge fund portfolios underscores their perceived long-term value, albeit with distinct paths forward.
UnitedHealth Group and Bristol-Myers Squibb offer distinct propositions for dividend investors. UNH provides robust, albeit pressured, growth and a diversified healthcare ecosystem, while BMY delivers a higher yield and attractive valuation, contingent on pipeline execution. Investors should consider their risk tolerance and investment horizon when choosing between these two healthcare titans, as both require careful monitoring of their respective industry and company-specific catalysts.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
